Twist Bioscience Q2 revenue $110.7M (+19% YoY); raises FY2026 revenue guidance to $442-447M

Twist Bioscience Corp

2026-Q2 EPS reported -$1.21 revenue$214,413,000

Record revenue $110.7M, 13th consecutive quarter of sequential growth; gross margin 51.6% (+2 pts YoY).
DSPS revenue $53.3M (+28% YoY); NGS revenue $57.4M (+12% YoY).
Net loss $44M ($0.71/share) vs $39.3M ($0.66/share) YoY; adjusted EBITDA loss improved to $13.3M from $14.8M.
Raised FY2026 revenue guidance to $442-447M; reiterates Q4 FY26 adjusted EBITDA breakeven.
Booked $7.2M litigation settlement cost for securities class action; entered bispecific licensing with Invenra.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Twist Bioscience Corp reported fiscal second quarter 2026 results: revenue $110.7 million, net income $44.0 million, EPS $0.71 per share. Guidance raised.

Period: fiscal second quarter 2026
Revenue: $110.7 million
Net income: $44.0 million
EPS: $0.71 per share
Guidance: raised
Result: reported results

Exact text from the filing

expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results — Record revenue of $110.7 million in 2QFY26 ; Increase of more than 19% over $92.8 million in 2QFY25; 13th consecutive quarter of sequential growth — — Gross margin of 51.6% in 2QFY26 ; Improvement of

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Twist Bioscience Corp filing history →

Source: SEC EDGAR

accession 0001581280-26-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.